AVI BioPharma Files IND For Clinical Trial Of Marburg Virus Treatment

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for a clinical trial to evaluate the Company’s antisense drug AVI-6003 for the treatment of Marburg virus infection. AVI plans to conduct the trial as part of its continued collaboration with the US Army Medical Research Institute of Infectious Diseases (USAMRIID).

More: continued here

Filed under: Tropical on December 19th, 2008